Psychedelic-Based Solutions

Proven Solutions to Stroke, Neurological Disorders and Mental Illnesses

In the United States, almost half of adults (46.4%) will experience a mental illness during their lifetime. In 2017, there were an estimated 46.6 million adults aged 18 or older in the United States with Any Mental Illness (AMI). This number represented 18.9% of all U.S. adults. Unmet needs are so high that The FDA designated psilocybin as a Breakthrough Therapy for Major/ Treatment-Resistant Depressive Disorder in Oct 2018 and Nov 2019 resp., acknowledging both the unmet medical need in this broad population and the potential role for psychedelics in providing significant improvements over existing therapies.

Psychedelics and Neurological Disorders

There has been recent interest in the therapeutic potential of psychedelics such as psilocybin and lysergic acid diethylamide (LSD), and in recent studies psychedelics have shown promise in treating a range of neuropsychiatric conditions. Modification of neural circuits associated with self-representation is thought to underlie some of this effect.
In the past two decades, research into the therapeutic potential of psychedelics has re-emerged, and there has been interest in the use of psychedelic compounds in a wide range of neuropsychiatric disorders. Studies have shown that psychedelics have a profound effect on neural activity, and are felt to ‘deconstrain’ networks in the brain, including those responsible for self-related processing.


Sign up to our newsletter and stay up to date